Pasithea Therapeutics (KTTA): Net earnings per share for the last 12 months

Pasithea Therapeutics (KTTA) focuses on neurodegeneration therapy, which impacts its debt load. The rolling year earnings per share visualize these costs, where the indicator value stands at -1.38. Stability is maintained through the diversification of biocomponent suppliers. The preclinical development of targeted JAK1 inhibitors creates potential for future capital optimization and asset value growth.
Summary analytical data breakdowns for pasitheaclinics.com (KTTA)

An investment audit of the issuer requires a deep analysis of the business's ability to generate real income. This metric is calculated by dividing the total annual net profit by the total number of shares. For the biotech company Pasithea Therapeutics (KTTA), this reflects the monetization efficiency of its clinic network and R&D developments. The TTM earnings per share chart captures the stability of the capitalization. The investor determines whether innovations are translating into financial results.